Persistent Elimination of ErbB-2/HER2-overexpressing Tumors Using Combinations of Monoclonal Antibodies: Relevance of Receptor Endocytosis

Proceedings of the National Academy of Sciences of the United States of America - United States
doi 10.1073/pnas.0812059106
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Proceedings of the National Academy of Sciences

Related search

Characterization of the Interleukin 2 Receptor Beta Chain Using Three Distinct Monoclonal Antibodies.

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
1989English

Study of the Regulation of ErbB Signaling by Receptor-Mediated Endocytosis

2002English

Genetic Prodrug Activation in erbB-2 Overexpressing Breast Cancer

Breast Cancer Research
Cancer ResearchOncology
1999English

Immuno-Histological Diagnosis of Lymphoproliferative Diseases by Selected Combinations of Antisera and Monoclonal Antibodies

British Journal of Cancer
Cancer ResearchOncology
1980English

Monoclonal Antibodies to Human Intermediate Filament Proteins: III. Analysis of Tumors

American Journal of Clinical Pathology
MedicineForensic MedicinePathology
1985English

Monoclonal Antibodies and Fc Fragments for Treating Solid Tumors

Biologics: Targets and Therapy
OncologyImmunologyGastroenterologyPharmacologyRheumatologyAllergy
2012English

Development and Clinical Application of Anti-Her2 Monoclonal and Bispecific Antibodies for Cancer Treatment

Experimental Hematology and Oncology
Cancer ResearchOncologyHematology
2017English

Ibrutinib Inhibits ERBB Receptor Tyrosine Kinases and HER2-Amplified Breast Cancer Cell Growth

Molecular Cancer Therapeutics
Cancer ResearchOncology
2016English

Prolactinoma ErbB Receptor Expression and Targeted Therapy for Aggressive Tumors

Endocrine
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy